Alzheimer's disease: Insights from Drosophila melanogaster models

Trends in Biochemical Sciences

Volumn 35, Issue 4, 2010, Pages 228-235

  Moloney, Aileen ^a,b,c   Sattelle, David B ^a   Lomas, David A ^b,c   Crowther, Damian C ^c,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DNA SEQUENCE; DROSOPHILA MELANOGASTER; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENOME; GENOMICS; HUMAN; HUNTINGTON CHOREA; MOLECULAR BIOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; REVIEW; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; HUMANS; MEMBRANE PROTEINS; PHENOTYPE;

DROSOPHILA MELANOGASTER;

EID: 77951016608     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2009.11.004     Document Type: Review

References (95)

1. Rubin G.M., et al. Comparative genomics of the eukaryotes. Science 2000, 287:2204-2215.
2. Goodstadt L., Ponting C.P. Phylogenetic reconstruction of orthology, paralogy, and conserved synteny for dog and human. PLoS Comput. Biol. 2006, 2:e133.
3. Pennisi E. Genetics. Working the (gene count) numbers: finally, a firm answer?. Science 2007, 316:1113.
4. Copley R.R. The animal in the genome: comparative genomics and evolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2008, 363:1453-1461.
5. Davidson E.H. The Regulatory Genome 2006, Academic Press.
6. Lai C.H., et al. Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome. Res. 2000, 10:703-713.
7. Luheshi L.M., et al. Systematic in vivo analysis of the intrinsic determinants of amyloid β Pathogenicity. PLoS Biol. 2007, 5:e290.
8. Baglioni S., et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 2006, 26:8160-8167.
9. Bucciantini M., et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 2004, 279:31374-31382.
10. Luheshi L.M., et al. Protein misfolding and disease: from the test tube to the organism. Curr. Opin. Chem. Biol. 2008, 12:25-31.
11. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
12. Selkoe D.J. Folding proteins in fatal ways. Nature 2003, 426:900-904.
13. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
14. Roberson E.D., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
15. Rapoport M., et al. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6364-6369.
16. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
17. Naslund J., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
18. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta. Neuropathol. 1991, 82:239-259.
19. Lambert M.P., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
20. Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
21. Gong Y., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10417-10422.
22. Cleary J.P., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
23. Townsend M., et al. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
24. Shankar G.M., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
25. Kayed R., et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279:46363-46366.
26. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
27. Eckert A., et al. Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med. 2008, 86:1255-1267.
28. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
29. Tartaglia G.G., et al. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 2008, 380:425-436.
30. Pawar A.P., et al. Prediction of " aggregation-prone" and " aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 2005, 350:379-392.
31. Chiti F., et al. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003, 424:805-808.
32. Iijima K., et al. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6623-6628.
33. Yang Y., et al. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J. Neurosci. 2003, 2557-2563.
34. Chatterjee S., et al. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 2009, 18:164-177.
35. Folwell J., et al. Aβ exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exp. Neurol. 2009, Sept 24 (Epub ahead of print).
36. Greeve I., et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 2004, 24:3899-3906.
37. Finelli A., et al. A model for studying Alzheimer's Aβ42-induced toxicity in Drosophila melanogaster. Mol. Cell Neurosci. 2004, 26:365-375.
38. Crowther D.C., et al. Intraneuronal Ab, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005, 132:123-135.
39. Stokin G.B., et al. Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum. Mol. Genet. 2008, 17:3474-3486.
40. Iijima K., et al. Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS ONE 2008, 3:e1703.
41. Lee V.M., et al. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
42. Goedert M., Jakes R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta. 2005, 1739:240-250.
43. Shulman J.M., Feany M.B. Genetic modifiers of tauopathy in Drosophila. Genetics 2003, 165:1233-1242.
44. Wittmann C.W., et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
45. Jackson G.R., et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
46. Crowther D.C., et al. A Drosophila model of Alzheimer's disease. Methods Enzymol. 2006, 412:234-255.
47. Rival T., et al. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur. J. Neurosci. 2009, 29:1335-1347.
48. Rival T., et al. Decreasing glutamate buffering capacity triggers oxidative stress and neuropil degeneration in the Drosophila brain. Curr. Biol. 2004, 14:599-605.
49. Slawson J.B., et al. High-resolution video tracking of locomotion in adult Drosophila melanogaster. JoVE 2009, 24. http://www.jove.com/index/details.stp?id=1096, doi:10.3791/1096.
50. Grover D., et al. Simultaneous tracking of movement and gene expression in multiple Drosophila melanogaster flies using GFP and DsRED fluorescent reporter transgenes. BMC Res. Notes. 2009, 2:58.
51. Grover D., et al. Simultaneous tracking of fly movement and gene expression using GFP. BMC Biotechnol. 2008, 8:93.
52. Blard O., et al. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum. Mol. Genet. 2007, 16:555-566.
53. Kaltenbach L.S., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007, 3:e82.
54. Bilen J., Bonini N.M. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet. 2007, 3:e177.
55. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
56. Ravikumar B., et al. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J. Cell. Sci. 2008, 121:1649-1660.
57. Jackson G.R., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
58. Cao W., et al. Identification of novel genes that modify phenotypes induced by Alzheimer's β-amyloid overexpression in Drosophila. Genetics 2008, 178:1457-1471.
59. Tan L., et al. The Toll-->NFκB signaling pathway mediates the neuropathological effects of the human Alzheimer's Aβ42 polypeptide in Drosophila. PLoS ONE 2008, 3:e3966.
60. Ittner L.M., et al. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284:20909-20916.
61. Hutton M., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
62. Chin J.Y., et al. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol. 2000, 59:966-971.
63. Augustinack J.C., et al. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta. Neuropathol. 2002, 103:26-35.
64. Perez M., et al. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J. Neurochem. 2000, 74:2583-2589.
65. Zhang B., et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 2004, 24:4657-4667.
66. Terry R.D., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
67. Gatz M., et al. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol. Aging. 2005, 26:439-447.
68. Grupe A., et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum. Mol. Genet. 2007, 16:865-873.
69. Harold D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
70. Lambert J.C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
71. Rogaeva E., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39(2):168-177.
72. Beecham G.W., et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am. J. Hum. Genet. 2009, 84:35-43.
73. Culetto E., Sattelle D.B. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 2000, 9:869-877.
74. Jones A.K., et al. Chemistry-to-gene screens in Caenorhabditis elegans. Nat. Rev. Drug. Discov. 2005, 4:321-330.
75. Buckingham S.D., et al. RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. Hum. Mol. Genet. 2004, 13(Spec No 2):R275-288.
76. Kamath R.S., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421:231-237.
77. Dietzl G., et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 2007, 448:151-156.
78. Jeibmann A., Paulus W. Drosophila melanogaster as a model organism of brain diseases. Int. J. Mol. Sci. 2009, 10:407-440.
79. Vosshall L.B., Stocker R.F. Molecular architecture of smell and taste in Drosophila. Annu. Rev. Neurosci. 2007, 30:505-533.
80. Fahrbach S.E. Structure of the mushroom bodies of the insect brain. Annu. Rev. Entomol. 2006, 51:209-232.
81. Strauss R. The central complex and the genetic dissection of locomotor behaviour. Curr. Opin. Neurobiol. 2002, 12:633-638.
82. Warrick J.M., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
83. Pokrzywa M., et al. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. Eur. J. Neurosci. 2007, 26:913-924.
84. Berg I., et al. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster. Neurodegener. Dis. 2009, 6:127-138.
85. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
86. Watson M.R., et al. A drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J. Biol. Chem. 2008, 283:24972-24981.
87. Chan Y.B., et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet. 2003, 12:1367-1376.
88. Mudher A., et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry. 2004, 9:522-530.
89. Torres T.T., et al. Gene expression profiling by massively parallel sequencing. Genome. Res. 2008, 18:172-177.
90. Ryder E., et al. The DrosDel deletion collection: a Drosophila genomewide chromosomal deficiency resource. Genetics 2007, 177:615-629.
91. Rorth P., et al. Systematic gain-of-function genetics in Drosophila. Development 1998, 125:1049-1057.
92. Rorth P. A modular misexpression screen in Drosophila detecting tissue-specific phenotypes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12418-12422.
93. Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118:401-415.
94. Osterwalder T., et al. A conditional tissue-specific transgene expression system using inducible GAL4. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12596-12601.
95. Kennerdell J.R., Carthew R.W. Heritable gene silencing in Drosophila using double-stranded RNA. Nat. Biotechnol. 2000, 18:896-898.